Objective
THE IMPACT OF SUCCESFUL DEVELOPMENT OF SUCH IN VITRO MODELS WOULD BE PROVISION OF METHODS FOR : SCREENING AND PREDICTING MORE ACCURATELY THE POTENTIAL THERAPEUTIC EFFICACY OF NEW DRUGS OR DRUG COMBINATIONS ; AND FOR EVALUATING AND REDUCING SIDE EFFECTS OF DRUGS AND/OR DRUG COMBINATIONS BASED ON A BETTER KNOWLEDGE OF THEIR METABOLISM AND THEIR MECHANISM OF ACTION.
Predictive in vitro models have been developed for assessing the therapeutic efficiency and the toxicity (mainly hepatoxicity), including metabolic profiles of anticancer drugs. These include: improving methods for primary culture of human cancer cells; selecting multidrug resistant human cancer cell lines; isolation, cryopreservation and culture of human hepatocytes; development of an organ slicing technique. The integrated set of in vitro models are routinely used in drug development.
SPECIFIC AIMS ARE DEVELOPED NEW APPROACH FOR INTEGRATING PHARMACOLLOGICAL, TOXICOLOGICAL AND METABOLIC CONCEPTS FOCUSED ON CANCER CHEMOTHERAPY.TO ACHIEVE THESE AIMS, EFFORTS WILL BE DEVOTED TO :
1.AN IMPROVED BASIC UNDERSTANDING AND NEW METHODOLOGICAL DEVELOPMENT OF THE SYSTEMS TO BE USED : IN DUBLIN (A) BY IMPROVING THE CONDITIONS FOR CELL CULTURES USED AS PREDICTORS FOR DRUG ACTIVITY;
IN MARSEILLE (B) BY IMPROVING THE RECOVERY OF HUMAN HEPATOCYTES AND BY DEVELOPING TECHNIQUES FOR CRYOPRESERVATION;
IN BRUSSELS (C) BY IMPROVING THE TECHNOLOGY OF SLICE PREPARATION AND THE CONDITIONS FOR THEIR INCUBATION.
2.THE DEVELOPMENT OF AN INTEGRATED STRATEGY : IN A, TO DEVELOP CELL CULTURE METHODS WHICH MIGHT ALLOW PREDICTION OF TISSUE-SPECIFIC PHARMACOLOGICAL EFFECTS AND SIDE-EFFECTS OF CANCER CHEMOTHERAPEUTIC AGENTS (WITH ALSO SOME REFERENCE TO ANTIBIOTICS) AND THEIR METABOLITES, AS WELL AS COMBINATIONS OF DIFFERENT DRUGS ;
IN C, TO EVALUATE THE POTENTIAL TOXICITY, MAINLY NEPHROTOXICITY (WITH REFERENCE TO HAPATOXICITY), OF DRUGS AND-OR THEIR METABOLITES BUT ALSO OF DRUG COMBINATIONS ;
IN B, TO PREDICT MORE RAPIDLY THE METABOLIC PROFILES AND THE ROLES OF THE METABOLITES IN THE OVERALL PHARMACOLOGICAL AND TECHNOLOGICAL CELLULAR RESPONSE TO DRUGS AND DRUG COMBINATIONS.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
- medical and health sciences basic medicine toxicology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.